Orphanet: Simple search

Search for a clinical trial

Other search option(s)

69 Result(s)

National clinical trial(s)

Multicentre, randomized, double-blind, prospective investigation on the effects of Immunoadsorption on cardiac function in patients with Dilated Cardiomyopathy (Phase IV) - DE Universitätsmedizin Greifswald Klinik und Poliklinik für Innere Medizin B

TITAN Study: Rapid Recovery of Left Ventricular Function in Patients With Takotsubo Syndrome Undergoing Systemic Infusion of Adenosine: a Randomized Controlled Trial A.O.U. di Ferrara - Nuovo Ospedale S.Anna - Sede di Cona Divisione di Cardiologia

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment - FR Institution: Information not provided - FR

AmyDara: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better - FR CHU de Limoges - Hôpital Dupuytren Service d'hématologie clinique et de thérapie cellulaire

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - DE Zentrum für Innere Medizin (Krehl-Klinik) Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - FR Universitätsklinikum Münster

An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy - IT Institution: Information not provided - IT

A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy - IT Fondazione IRCCS Policlinico San Matteo Dipartimento di Medicina Molecolare

Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis (Phase I) Hospital de Santo António - Centro Hospitalar do Porto Unidade Clínica de Paramiloidose

Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients With Transthyretin Amyloidosis (Phase II/III) Hospital de Santo António - Centro Hospitalar do Porto Unidade Clínica de Paramiloidose

Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients With Transthyretin Amyloidosis (Phase II/III) Hospital de Sta. Maria - Centro Hospitalar de Lisboa Norte, EPE. Serviço de Neurologia

An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression Post-Orthotopic Liver Transplant (Phase III) - ES Hospital Juan Ramón Jiménez

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - ES Hospital Clínic de Barcelona Servicio de Hematología

ReDox: A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ES Hospital Clínic de Barcelona Servicio de Hematología

An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression Post-Orthotopic Liver Transplant (Phase III) - ES Hospital Universitari de Bellvitge

A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis - UK Queen Elizabeth Hospital

A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects Alnylam Pharmaceuticals, Inc.

CARDIO-TTRansform: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) - AT Institution: Information not provided - AT

HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) - AT Institution: Information not provided - AT

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy - FR CHU Paris-Sud - Hôpital de Bicêtre Service de neurologie - CRMR NNERf

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study (Phase III) - FR CHU Paris-Sud - Hôpital de Bicêtre Service de neurologie - CRMR NNERf

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - FR CHU Paris-Sud - Hôpital de Bicêtre Service de neurologie - CRMR NNERf

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran (Phase III) - ES Hospital Juan Ramón Jiménez Servicio de Medicina Interna

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran (Phase III) - ES Hospital Son Llàtzer Unidad de Medicina Interna

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - ES Hospital Clínic de Barcelona

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - ES Hospital Universitari Vall d'Hebron

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) - ES Hospital Universitario y Politécnico La Fe Servicio de Neurología

A phase 3 multicenter, randomized, double-blind, extension study to evaluate the safety of daily oral dosing of tafamidis meglumine (PF-06291826) 20 mg or 80 mg in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM) - ES Hospital Universitario da Coruña

ATTRIBUTE-CM Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy - ES Institution: Information not provided - ES

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis - ES Institution: Information not provided - ES

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran (Phase III) - ES Hospital Clínico San Carlos

AMILCA-DIFLU: Unicentre, open, uncontrolled clinical trial to assess the morphological, biochemical and functional effects of Diflunisal treatment in patients with transthyretin cardiac amyloidosis (Phase II-III) - ES Hospital Universitario Fundación Jiménez Díaz Servicio de Cardiología

A phase 3 multicenter, randomized, double-blind, extension study to evaluate the safety of daily oral dosing of tafamidis meglumine (PF-06291826) 20 mg or 80 mg in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM) - ES Hospital Universitario Puerta de Hierro - Majadahonda

CARDIO-TTRansform: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) - ES Hospital Universitario Puerta de Hierro - Majadahonda Servicio de Cardiología

CARDIO-TTRansform: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) - ES Hospital Clínico Universitario Virgen de la Arrixaca Servicio de Cardiología

Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-Blind, Placebo-Controlled Study (Phase II-III) University Hospital of Umeå Department of Medicine

A Pilot study of Response to Velcade combination chemotherapy in AL amyloidosis (REVEAL) Cancer Research UK & UCL Cancer Trials Centre

ISIS 420915-CS2: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy - UK University College London Medical School and Royal Free Hospital National Amyloidosis Centre, Division of Medicine

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) - GB Institution: Information not provided - UK

Fx-005: Safety and efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study - UK FoldRx Pharmaceuticals, Inc. FoldRx Pharmaceuticals

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP) (Phase III) - US Icahn School of Medicine at Mount Sinai

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy - US Institution: Information not provided - US

Multinational clinical trial(s)

A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (Prematurely ended) Institution: Information not provided - IE

A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy Fondazione IRCCS Policlinico San Matteo Dipartimento di Medicina Molecolare

An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy Oncopeptides AB

A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis - coordination Alnylam Pharmaceuticals, Inc.

An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant Alnylam Pharmaceuticals, Inc.

AMYDARA: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better Institution: Information not provided - US

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02 Alnylam Pharmaceuticals, Inc.

Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-Blind, Placebo-Controlled Study (Phase II/III) (coordination) FoldRx Pharmaceuticals, Inc. FoldRx Pharmaceuticals

Multicentre, randomized, double-blind, prospective investigation on the effects of Immunoadsorption on cardiac function in patients with Dilated Cardiomyopathy (Phase IV) - DE
Universitätsmedizin Greifswald

Klinik und Poliklinik für Innere Medizin B

TITAN Study: Rapid Recovery of Left Ventricular Function in Patients With Takotsubo Syndrome Undergoing Systemic Infusion of Adenosine: a Randomized Controlled Trial
A.O.U. di Ferrara - Nuovo Ospedale S.Anna - Sede di Cona

Divisione di Cardiologia

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment - FR
Institution: Information not provided - FR

AmyDara: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better - FR
CHU de Limoges - Hôpital Dupuytren

Service d'hématologie clinique et de thérapie cellulaire

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - DE
Zentrum für Innere Medizin (Krehl-Klinik)

Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - FR
Universitätsklinikum Münster

An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy - IT
Institution: Information not provided - IT

A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy - IT
Fondazione IRCCS Policlinico San Matteo

Dipartimento di Medicina Molecolare

Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis (Phase I)
Hospital de Santo António - Centro Hospitalar do Porto

Unidade Clínica de Paramiloidose

Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients With Transthyretin Amyloidosis (Phase II/III)
Hospital de Santo António - Centro Hospitalar do Porto

Unidade Clínica de Paramiloidose

Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients With Transthyretin Amyloidosis (Phase II/III)
Hospital de Sta. Maria - Centro Hospitalar de Lisboa Norte, EPE.

Serviço de Neurologia

An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression Post-Orthotopic Liver Transplant (Phase III) - ES
Hospital Juan Ramón Jiménez

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - ES
Hospital Clínic de Barcelona

Servicio de Hematología

ReDox: A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ES
Hospital Clínic de Barcelona

Servicio de Hematología

An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression Post-Orthotopic Liver Transplant (Phase III) - ES
Hospital Universitari de Bellvitge

A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis - UK
Queen Elizabeth Hospital

A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects
Alnylam Pharmaceuticals, Inc.

CARDIO-TTRansform: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) - AT
Institution: Information not provided - AT

HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) - AT
Institution: Information not provided - AT

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy - FR
CHU Paris-Sud - Hôpital de Bicêtre

Service de neurologie - CRMR NNERf

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study (Phase III) - FR
CHU Paris-Sud - Hôpital de Bicêtre

Service de neurologie - CRMR NNERf

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - FR
CHU Paris-Sud - Hôpital de Bicêtre

Service de neurologie - CRMR NNERf

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran (Phase III) - ES
Hospital Juan Ramón Jiménez

Servicio de Medicina Interna

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran (Phase III) - ES
Hospital Son Llàtzer

Unidad de Medicina Interna

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - ES
Hospital Clínic de Barcelona

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) (Phase III) - ES
Hospital Universitari Vall d'Hebron

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) - ES
Hospital Universitario y Politécnico La Fe

Servicio de Neurología

A phase 3 multicenter, randomized, double-blind, extension study to evaluate the safety of daily oral dosing of tafamidis meglumine (PF-06291826) 20 mg or 80 mg in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM) - ES
Hospital Universitario da Coruña

ATTRIBUTE-CM Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy - ES
Institution: Information not provided - ES

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis - ES
Institution: Information not provided - ES

A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with Patisiran (Phase III) - ES
Hospital Clínico San Carlos

AMILCA-DIFLU: Unicentre, open, uncontrolled clinical trial to assess the morphological, biochemical and functional effects of Diflunisal treatment in patients with transthyretin cardiac amyloidosis (Phase II-III) - ES
Hospital Universitario Fundación Jiménez Díaz

Servicio de Cardiología

A phase 3 multicenter, randomized, double-blind, extension study to evaluate the safety of daily oral dosing of tafamidis meglumine (PF-06291826) 20 mg or 80 mg in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM) - ES
Hospital Universitario Puerta de Hierro - Majadahonda

CARDIO-TTRansform: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) - ES
Hospital Universitario Puerta de Hierro - Majadahonda

Servicio de Cardiología

CARDIO-TTRansform: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) - ES
Hospital Clínico Universitario Virgen de la Arrixaca

Servicio de Cardiología

Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-Blind, Placebo-Controlled Study (Phase II-III)
University Hospital of Umeå

Department of Medicine

A Pilot study of Response to Velcade combination chemotherapy in AL amyloidosis (REVEAL)
Cancer Research UK & UCL Cancer Trials Centre

ISIS 420915-CS2: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy - UK
University College London Medical School and Royal Free Hospital

National Amyloidosis Centre, Division of Medicine

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) - GB
Institution: Information not provided - UK

Fx-005: Safety and efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): a Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study - UK
FoldRx Pharmaceuticals, Inc.

FoldRx Pharmaceuticals

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP) (Phase III) - US
Icahn School of Medicine at Mount Sinai

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy - US
Institution: Information not provided - US

A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (Prematurely ended)
Institution: Information not provided - IE

A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy
Fondazione IRCCS Policlinico San Matteo

Dipartimento di Medicina Molecolare

An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy
Oncopeptides AB

A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis - coordination
Alnylam Pharmaceuticals, Inc.

An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant
Alnylam Pharmaceuticals, Inc.

AMYDARA: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better
Institution: Information not provided - US

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02
Alnylam Pharmaceuticals, Inc.

Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-Blind, Placebo-Controlled Study (Phase II/III) (coordination)
FoldRx Pharmaceuticals, Inc.

FoldRx Pharmaceuticals